Based on recent financial filings, GoodRx Holdings, Inc. (GDRX) and ARS Pharmaceuticals, Inc. are involved in legal proceedings that had significant developments around March 2025, though the nature and filing dates of these lawsuits vary.
GoodRx Holdings, Inc. (GDRX)
GoodRx is facing a securities class action lawsuit, initially filed on April 22, 2024, alleging violations of Sections 10(b) and 20(a) of the Exchange Act and Rule 10b-5. The plaintiffs claim that GoodRx and certain executive officers failed to disclose risks related to a grocery chain's actions that impacted the acceptance of their discounted prescription drug pricing.
Key developments around March 2025 include:
- On January 10, 2025, the plaintiffs filed their opposition to GoodRx's motion to dismiss the class action lawsuit.
- GoodRx filed its response to the opposition on February 11, 2025.
- On February 20, 2025, several derivative lawsuits, based on similar allegations, were consolidated and stayed pending the resolution of the securities class action's motion to dismiss.
- On April 23, 2025, the court granted GoodRx's motion to dismiss the securities class action, though it was dismissed without prejudice and with leave for the plaintiffs to amend their complaint.
Regarding potential liabilities, GoodRx recognized a probable loss of $25.0 million within accrued expenses and other current liabilities as of December 31, 2024, which remained accrued as of March 31, 2025. This amount represents their best judgment of the probable loss. However, the company also noted that it is reasonably possible an incremental loss may have been incurred for the indemnification of certain parties, but a specific loss or range of loss is not reasonably estimable at this time.
ARS Pharmaceuticals, Inc.
ARS Pharmaceuticals, Inc. was sued on March 25, 2025, by Aptargroup, Inc. and Aptar France SAS. This lawsuit, filed in the United States District Court for the Southern District of New York, alleges violations of the Defend Trade Secrets Act, misappropriation of trade secrets under New York state law, and various breaches of contract.
ARS Pharmaceuticals intends to vigorously defend itself in this matter. The company cannot predict the outcome, and an unfavorable resolution could have a material adverse effect on its business, results of operations, and financial condition. As of March 31, 2025, ARS Pharmaceuticals has not recorded a liability for this lawsuit because any possible loss or range of loss cannot be reasonably estimated.
